Three months after a successful initial public offering, Latigo Biotherapeutics will be moving forward with a new chief executive. Thousand Oaks-based Latigo, which specializes in creating non-opioid pain medicines, announced Nov. 5 that it has appointed Todd N. Smith as president and CEO, effective immediately. Smith has worked as an independent director on Latigo's board…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
